Septerna, Inc. (SEPN) - Stock Analysis
Last updated: Mar 15, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Phase 1 trial initiations, significant loss reduction, strong cash reserves through 2029, and recent 5.5% price gain with positive technicals support Septerna as a hot short-term biotech idea amid ongoing clinical developments.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠Sustained losses ⢠High valuation SEPN is balance-sheet strong with positive free cash flow and low leverage but remains profit-challenged due to large operating losses, heavy R&D versus revenue, and a stretched valuation.
Price Behavior
Key Price Behavior Insights: ⢠Below last-month SMA ⢠Near mid-$25s support ⢠Resistance $30â$31 Support Level: $25.00 (mid-$25s) Resistance Level: $30.00â$31.00 SEPN has lost short-term momentum: after peaking in late February the stock closed well below its last-month SMA (high-$28s) and is trading near mid-$25s supportâbreak below on heavy volume would likely lead to further downside while reclaiming $30â$31 is needed to resume the uptrend.
Sentiment & News
Key News Insights: ⢠Phase 1 win ⢠Phase 2b planned ⢠Cash runway Septerna posted robust Phase 1 SEP-631 data supporting a Phase 2b start and SEP-479 advancement with cash runway into 2029, despite a slight Q4 EPS miss and stock volatility after an insider sale. #R&Dprogressâ
AI Summary
Septerna has shifted from a speculative, highâburn biotech to a catalystâdriven, deârisked development company with a multiâyear runway (into ~2029) and nearâterm value driversâSEPâ631 Phase 2b (H2 2026) and SEPâ479 Phase 1âmaking upcoming clinical readouts and milestone receipts the primary drivers of upside. Actionable: consider initiating or adding positions at/below the midâ$20s support, and monitor Phase 2b results, milestone/deferredârevenue recognition, and any clinical delays or safety signals that would materially reprice the stock.
Description
Septerna is a clinical-stage biotechnology company that discovers and develops oral small-molecule modulators of G proteinâcoupled receptors for endocrine, immune/inflammatory and metabolic disorders. Its pipeline includes a PTH1R agonist for hypoparathyroidism, candidates targeting mast cellâmediated urticaria and TSHR-related thyroid conditions, and single- and multi-incretin receptor agonists for obesity and type 2 diabetes. The company was incorporated in 2019, changed its name from GPCR NewCo to Septerna in June 2021, and is headquartered in South San Francisco, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Nov 17 | Nov 24 | SEPN | Septerna, Inc. | Phase 1 trial initiations, significant loss reduction, strong cash reserves through 2029, and recent 5.5% price gain with positive technicals support Septerna as a hot short-term biotech idea amid ongoing clinical developments. | Closed | +31.8% |